XLS Stock Overview

Focuses on the development and commercialization of research projects in the life sciences sector. More details

XLS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	4/6
Financial Health	3/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (3.4x) is below the German market (18.9x)

Earnings grew by 130.4% over the past year

Risk Analysis

Shares are highly illiquid

Does not have meaningful revenue (CHF835K)

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Xlife Sciences AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Xlife Sciences
Historical stock prices
Current Share Price	CHF 21.20
52 Week High	CHF 23.60
52 Week Low	CHF 20.40
Beta	0.39
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-20.90%
Change since IPO	-35.07%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	XLS	DE Life Sciences	DE Market
7D	1.4%	-2.6%	-0.9%
1Y	n/a	-5.8%	14.1%

Return vs Industry: Insufficient data to determine how XLS performed against the German Life Sciences industry.

Return vs Market: Insufficient data to determine how XLS performed against the German Market.

Price Volatility

Is XLS's price volatile compared to industry and market?
XLS volatility
XLS Average Weekly Movement	n/a
Life Sciences Industry Average Movement	7.1%
Market Average Movement	6.5%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: XLS's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine XLS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	17	Oliver Baumann	www.xlifesciences.ch

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company’s project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services.

Xlife Sciences AG Fundamentals Summary

How do Xlife Sciences's earnings and revenue compare to its market cap?
XLS fundamental statistics
Market cap	€124.39m
Earnings (TTM)	€36.76m
Revenue (TTM)	€895.36k

3.4x

P/E Ratio

138.9x

P/S Ratio

Is XLS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XLS income statement (TTM)
Revenue	CHF 834.88k
Cost of Revenue	CHF 285.35k
Gross Profit	CHF 549.52k
Other Expenses	-CHF 33.73m
Earnings	CHF 34.28m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Sep 23, 2025

Earnings per share (EPS)	5.97
Gross Margin	65.82%
Net Profit Margin	4,105.62%
Debt/Equity Ratio	14.9%

How did XLS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/24 20:09
End of Day Share Price	2025/05/23 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xlife Sciences AG is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Daniel Jelovcan	Stifel, Equities Research
Ulrich Huwald	Warburg Research GmbH